NASDAQ:RETA - Reata Pharmaceuticals Stock Price, Forecast & News

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Reata Pharmaceuticals Inc (NASDAQ:RETA) announced its quarterly earnings results on Wednesday, February, 19th. The company reported ($5.91) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($2.21) by $3.70. The firm had revenue of $2.67 million for the quarter, compared to analyst estimates of $8.04 million. Reata Pharmaceuticals had a negative return on equity of 766.88% and a negative net margin of 1,094.28%. The business's revenue was down 68.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.86) earnings per share. View Reata Pharmaceuticals' Earnings History.

Reata Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Reata Pharmaceuticals.

8 brokers have issued 1 year price objectives for Reata Pharmaceuticals' shares. Their forecasts range from $130.00 to $362.00. On average, they expect Reata Pharmaceuticals' stock price to reach $278.13 in the next twelve months. This suggests a possible upside of 31.7% from the stock's current price. View Analyst Price Targets for Reata Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Reata Pharmaceuticals.

Media stories about RETA stock have been trending negative on Saturday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Reata Pharmaceuticals earned a news impact score of -2.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Reata Pharmaceuticals.

Some companies that are related to Reata Pharmaceuticals include Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Ono Pharmaceutical (OPHLF) and Bausch Health Companies (BHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), First Financial Bankshares (FFIN), Precision Drilling (PDS), Synlogic (SYBX), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Archrock (AROC), Targa Resources (TRGP), Gilead Sciences (GILD) and AbbVie (ABBV).

(RETA) raised $60 million in an IPO on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

Reata Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (4.11%), State Street Corp (1.69%), FMR LLC (1.19%), Geode Capital Management LLC (1.12%), Renaissance Technologies LLC (0.80%) and Goldman Sachs Group Inc. (0.54%). Company insiders that own Reata Pharmaceuticals stock include Cpmg Inc, Elaine Castellanos, James Edward Bass, James W Traweek Jr, James Warren Huff, Jason Douglas Wilson and Keith Wayne Ward. View Institutional Ownership Trends for Reata Pharmaceuticals.

RETA stock was sold by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Farallon Capital Management LLC, Loomis Sayles & Co. L P, Candriam Luxembourg S.C.A., Amundi Pioneer Asset Management Inc. and King Luther Capital Management Corp. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Elaine Castellanos, James Edward Bass, James Warren Huff, Jason Douglas Wilson and Keith Wayne Ward. View Insider Buying and Selling for Reata Pharmaceuticals.

RETA stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Pictet Asset Management Ltd., Sectoral Asset Management Inc, Columbus Circle Investors, State Street Corp, Geode Capital Management LLC and Assenagon Asset Management S.A.. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include Cpmg Inc, James Edward Bass and James W Traweek Jr. View Insider Buying and Selling for Reata Pharmaceuticals.

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RETA stock can currently be purchased for approximately $211.14.

Reata Pharmaceuticals has a market capitalization of $6.39 billion and generates $26.52 million in revenue each year. The company earns $-80,550,000.00 in net income (profit) each year or ($9.54) on an earnings per share basis. Reata Pharmaceuticals employs 123 workers across the globe.View Additional Information About Reata Pharmaceuticals.

The official website for Reata Pharmaceuticals is http://www.reatapharma.com/.

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The company can be reached via phone at 972-865-2219 or via email at [email protected]